Neurocrine Biosciences | Le Coût Des Ventes



Cost Of Sales Changement Date
AbbVie USD 4.35B 344M 2025-06
Acadia Pharmaceuticals USD 20.73M 342K 2025-06
Agios Pharmaceuticals USD 1.7M 617K 2025-06
ALKERMES USD 49.46M 263K 2025-06
Alnylam Pharmaceuticals USD 142.95M 71.91M 2025-06
Amgen USD 3.01B 406M 2025-06
Biogen USD 605M 24.3M 2025-06
BioMarin Pharmaceutical USD 154.94M 3.38M 2025-06
Cytokinetics 112.55M 12.71M 2025-06
Dynavax Technologies USD 14.04M 13.5M 2025-06
Exelixis USD 19.47M 298K 2025-07
Gilead Sciences USD 1.5B 39M 2025-06
Halozyme Therapeutics USD 64.12M 15.72M 2025-06
Incyte USD 78.77M 10.96M 2025-06
Ionis Pharmaceuticals USD 4.15M 3.15M 2025-06
Neurocrine Biosciences USD 11.3M 2.1M 2025-06
Pfizer USD 4.99B 2.4B 2025-06
Prothena 970K 4.78M 2024-09
Regeneron Pharmaceuticals USD 530.2M 264.7M 2025-06
Repligen USD 91.22M 12.81M 2025-06
Sarepta Therapeutics USD 153.22M 15.66M 2025-06
Teva Pharmaceutical Industries USD 2.07B 97M 2025-06
Ultragenyx Pharmaceutical USD 23M 5.66M 2025-06
Vertex Pharmaceuticals USD 407.5M 44.5M 2025-06


Neurocrine Biosciences Le Coût Des Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.